Search

Your search keyword '"Asghar, Muhammad Sohaib"' showing total 540 results
Start Over Author "Asghar, Muhammad Sohaib"
540 results on '"Asghar, Muhammad Sohaib"'

8. Physician experiences with teleconsultations amidst conflict in Sudan

Author

Eljack, Mohammed Mahmmoud Fadelallah, Elhadi, Yasir Ahmed Mohammed, Mahgoub, Esra Abdallah Abdalwahed, Ahmed, Khabab Abbasher Hussien Mohamed, Mohamed, Malaz Tarig Abd Alla, Elnaiem, Walaa, Mohamedsharif, Asma, Nour, Alshareef B., Muhammed, Abubakr Elsadig Musa, Gebril, Mohammed Salah M., Asghar, Muhammad Sohaib, and El-Osta, Austen

Published
2023
Full Text
View/download PDF

14. Long-term outcomes of titanium-nitride-oxide coated stents and drug-eluting stents in acute coronary syndrome: A systematic review and meta-analysis

Author

Fahim, Muhammad Ahmed Ali, primary, Salman, Afia, additional, Khan, Hira Anas, additional, Hasan, Syed Muhammad, additional, Bhojani, Muskan Fatima, additional, Aslam, Sarah, additional, Haq, Amna Zia Ul, additional, Bejugam, Vishal Reddy, additional, Nasir, Beena Muntaha, additional, Gul, Wajiha, additional, Moeed, Abdul, additional, Abdalla, Abdelrahman S, additional, Majid, Muhammad, additional, Asghar, Muhammad Sohaib, additional, and Hasibuzzaman, Md Al, additional

Published
2024
Full Text
View/download PDF

18. Pattern of novel psychoactive substance use among patients presented to the poison control centre of Ain Shams University Hospitals, Egypt: A cross-sectional study

Author

Hashim, Ahmed, Mohammed, Nouran A., Othman, AlFadl, Gab-Allah, Mohab A.K., Al-Kahodary, Ahmed H.M., Gaber, Eslam R., Hassan, Ahmed M., Aranda, Mahmoud, Hussien, Rania, Mokhtar, Amany, Islam, Md. Saiful, Lee, Ka Yiu, Asghar, Muhammad Sohaib, Tahir, Muhammad Junaid, and Yousaf, Zohaib

Published
2022
Full Text
View/download PDF

36. Evaluating the safety and efficacy of zuranolone in the management of major depressive disorder and postpartum depression, with or without concurrent insomnia: a rigorous systematic review and meta-analysis.

Author

Raja, Adarsh, Ahmed, Saboor, Ali Siddiqui, Muhammad Basit, Mir, Syeda Lamiya, Kumar, Rakesh, Ahmed, Muhammad, Raja, Sandesh, Bin Amin, Shafin, Ur Rahman, Hafsah Alim, Deepak, Fnu, and Asghar, Muhammad Sohaib

Subjects
POSTPARTUM depression, MENTAL depression, HAMILTON Depression Inventory, INSOMNIA, DYSTHYMIC disorder
Abstract

Introduction: Major depressive disorder (MDD), postpartum depression (PPD), and insomnia are neuropsychological conditions in which zuranolone is used to improve symptoms and prognosis of the disorder. This meta-analysis aimed to determine the efficacy of zuranolone in comparison to other drugs used for treating these conditions. Methods: This meta-analysis included patients aged between 18 and 75 years who were diagnosed with major depressive disorder and postpartum depression with or without insomnia and were administered zuranolone for treatment. Only randomized controlled trials (RCTs) were included, and animal studies were excluded. The databases used were PubMed, Scopus, Cochrane, and Clinicaltrials.gov, with MeSH terms and relevant keywords for (Zuranolone) and (Depression). The Cochrane risk of bias tool was used for quality assessment. Results: The meta-analysis included eight RCTs that analyzed data from 2031 patients. The meta-analysis revealed statistically significant changes in the Hamilton Depression Rating Scale (HAM-D), Montgomery-Åsberg Depression Rating Scale (MADRS), Hamilton Anxiety Rating Scale (HAM-A), and treatmentemergent adverse effects (TEAE) scores in the PPD subgroup. HAM-D and TEAEs scores were also significant in the MDD subgroup, but the changes in the MADRS, HAM-A, and Bech-6 scores were insignificant. Serious adverse events were insignificant in all subgroups. Conclusion: Meta-analysis found a significant improvement in depressive symptoms with zuranolone treatment, especially on day 15. This suggests that zuranolone is a promising therapeutic option for patients with MDD and PPD with or without insomnia. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Role of soluble urokinase type plasminogen activator receptor (suPAR) in predicting mortality, readmission, length of stay and discharge in emergency patients: A systematic review and meta analysis

Author

Rehan, Syeda Tayyaba, primary, Hussain, Hassan ul, additional, Ali, Eman, additional, Kumar, Kanwal Ashok, additional, Tabassum, Shehroze, additional, Hasanain, Muhammad, additional, Shaikh, Asim, additional, Ali, Gibran, additional, Yousaf, Zohaib, additional, and Asghar, Muhammad Sohaib, additional

Published
2023
Full Text
View/download PDF

45. Toxicities of CAR T-cell therapy: a review of current literature

Author

Yasmin, Farah, primary, Ismail Shah, Syed Muhammad, additional, Rani, Anooja, additional, Kazmi, Sana, additional, Savul, Ilma Saleh, additional, Ukrani, Janta, additional, Khan, Farmanullah, additional, Hasan, Chaudhary Ahmed, additional, Rathore, Navin, additional, Syed, Maria, additional, Keswani, Shiwani, additional, Surkahsha, FNU, additional, Mal, Doongro, additional, Kumar, Dileep, additional, and Asghar, Muhammad Sohaib, additional

Published
2023
Full Text
View/download PDF

47. Exposure to, understanding of and interest in interventional radiology among Pakistani medical students: a cross-sectional study

Author

Chattha, Muneeb, primary, Tahir, Muhammad Junaid, additional, Zia, Ahmad, additional, Chattha, Maha, additional, Tariq, Waleed, additional, Masood, Muhammad Faiq, additional, Sani, Salman, additional, Yousaf, Zohaib, additional, Eljack, Mohammed Mahmmoud Fadelallah, additional, and Asghar, Muhammad Sohaib, additional

Published
2023
Full Text
View/download PDF

49. Trends in Age-Adjusted Cardiovascular Mortality Rates with Hyperlipidemia among the United States Population, from 1999–2023: A CDC Wonder Database Study.

Author

Brands, Chad, Ekpendu, Abuoma, Colaco, Lanson, and Asghar, Muhammad Sohaib

Subjects
CARDIOVASCULAR disease related mortality, MORTALITY, HYPERLIPIDEMIA, AGE distribution, CONFERENCES & conventions, SOCIODEMOGRAPHIC factors, DISEASE complications
Abstract

Despite the progress made in managing hyperlipidemia in recent years, the mortality trends among the general population in the United States remain understudied. The lack of evidence in the demographic variations hampers the ability to implement evidence-based interventions on community-based levels. Our synthesis is to analyze the trends in hyperlipidemia-related mortality among United States residents by demographic characteristics such as age, gender, race or ethnicity, urbanization, and census region. Furthermore, state-wise age-adjusted mortality rates (AAMR) and county-wise data for highly prevalent states were subsequently analyzed. Prior studies have reported cardiovascular mortality rates in general, but they lack sufficiently updated data and trends among variable demographic groups suffering from hyperlipidemia. Furthermore, there haven't been any prior studies conducted to show specific correlations between mortality rates and certain geographically vulnerable areas. We abstracted national mortality data from the multiple cause of death/underlying case of death files in the CDC WONDER database retrieved from death certificates nationwide. The ICD-10 codes (E78.0-E78.9) were used to identify any type of hyperlipidemia-related deaths (including familial hypercholesterolemia) among the United States population from 1999 to 2023 in the multiple causes of death section. While ICD codes for cardiovascular (circulatory) system were identified by using I00–I99 for the underlying cause of death as a sensitivity analysis to only measure cardiovascular-related mortality in the hyperlipidemic population. Trends in age-adjusted mortality rate (AAMR) were assessed using joinpoint regression analysis (version 5.0.2) and the data was reported per 100,000 population. For 10-year increment age groups, only crude mortality rates were reported. Results were expressed as annual percentage changes (APC), average annual percentage changes (AAPC), and 95% confidence intervals (CI). For urbanization, the 2013 NCHS Urban-Rural Classification Scheme for Counties was used. Between 1999 and 2023, a total of 639,786 hyperlipidemia patients died secondary to cardiovascular causes within the United States (AAMR = 7.1 per 100,000; 95% CI: 7.0–7.2). Overall mortality trends increased at an annual rate of 6.21% (95% CI: 5.41–7.01) and were much higher in females from 1999–2006 and then 2018–2023; however, in the male population, APC was evidently higher in 1999–2006 and 2018–2021, respectively. Specifically, the trends in crude mortality rate would increase with each age group in 10-year increments, with the most steep rises from 1999–2004 and then 2018 onwards (P<0.001). Hispanic race is least affected amongst all subgroups; however, both non-Hispanic whites and more recently non-Hispanic blacks were increasingly highly affected (from 2018 onwards). Both suburban and rural areas (after 2019) are increasingly prevalent across the rural-urban divide (P<0.001). States in the top 90th percentile included Vermont (crude rate = 17.12), West Virginia (crude rate = 14.07), Hawaii (crude rate = 13.67), North Dakota (crude rate = 13.61), Rhode Island (crude rate = 13.38), and Iowa (crude rate = 13.18). Cardiovascular mortality among the US population with a diagnosis of hyperlipidemia has been anticipated to be increasing overall from 1999 to 2023, but with varying trends by age groups, gender, race/ethnicity, urbanization, and census region. This study will highlight the need for enhanced public health surveillance to better understand the scope of hyperlipidemia-related cardiovascular mortality and identify high-risk demographic and regional subgroups for targeted interventions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results